3篇
您的检索式：作者名="Yuting Zuo"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Artemisinin analogue SM934 protects against lupus-associated antiphospholipid syndrome via activation of Nrf2 and its targets显示文摘Kidney is a major target organ in both antiphospholipid syndrome(APS)and systemic lupus erythematosus(SLE).The etiology of antiphospholipid syndrome nephropathy associated lupus nephritis(APSN-LN)is intricate and remains largely unrevealed.We proposed in present work,that generation of antiphospholipid antibodies(aPLs),especially those directed towards the oxidized neoepitopes,are largely linked with the redox status along with disease progression.Moreover,we observed that compromised antioxidative capacity coincided with turbulence of inflammatory cytokine profile in the kidney of male NZW×BXSB F1 mice suffered from APSN-LN.SM934 is an artemisinin derivative that has been proved to have potent immunosuppressive properties.In current study,we elaborated the therapeutic benefits of SM934 in male NZW×BXSB F1 mice,a murine model develops syndrome resembled human APS associated with SLE,for the first time.SM934 treatment comprehensively impeded autoantibodies production,inflammatory cytokine accumulation and excessive oxidative stress in kidney.Among others,we interpreted in present work that both anti-inflammatory and antioxidative effects of SM934 is closely correlated with the enhancement of Nrf2 signaling and expression of its targets.Collectively,our finding confirmed that therapeutic strategy simultaneously exerting antioxidant and anti-inflammatory efficacy provide a novel feasible remedy for treating APSN-LN. | Zemin Lin Yuting Liu Li Chen Shiqi Cao Yueteng Huang Xiaoqian Yang Fenghua Zhu Wei Tang Shijun He Jianping Zuo | 2021 | Science China(Life Sciences)2021，64，10： | 2 |
| 2 | Repression of interferon regulatory factor-4(IRF4)hyperactivation restricts murine lupus显示文摘Dear Editor,Hyperactivation of the type I interferon(IFN)signature has been observed in several systemic autoimmune conditions,and the type I IFN receptor antagonist Saphnelo(anifrolumab-fnia)has been approved in 2021 by the Food and Drug Administration(FDA)in the US.The launch of Saphnelo marked the only new treatment approved for systemic lupus erythematosus(SLE)in more than 10 years. | Shijun He Huihua Ding Li Chen Yiwei Shen Yuting Liu Fenghua Zhu Xiaoqian Yang Nan Shen Zemin Lin Jianping Zuo | 2023 | Signal Transduction and Targeted Therapy2023，8，6： | 1 |
| 3 | A tetravalent single-chain antibody-streptaxidin fusion protein for pretargeted lymphoma therapy 显示文摘 | Jody Schultz Yukang Lin James Sanderson Yuting Zuo Diane Stone Robert Mallett Sibylle Wilbert Donald Axworthy | 2000 | Cancer Research2000，60，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员